HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Halozyme Therapeutics (HALO) Tops Q4 EPS by 18c; Guides FY23
February 21, 2023 4:04 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181 million versus the consensus estimate of $192.05 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 revenue of $815-845 million, versus the consensus of... More
